Product Description
Colistimethate sodium contains the pentasodium salt of the penta(methanesulfonic acid) derivative of colistin A as the major component and a small proportion of the petasodium salt of the pentamethanesulfonate derivative of colistin B. Colistins are cyclic polypeptides produced from Bacillus colistinus or B. polymyxa and function as a surfactant which penetrates into and disrupts the bacterial cell membrane, thereby resulting in bactericidal effect. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/colistimethate-sodium)
Mechanisms of Action: Cell Wall Antagonist,Gram- Bacteria Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | France | Greece | Hong Kong | Hungary | India | Ireland | Italy | Lebanon | Malaysia | Mexico | New Zealand | Norway | Pakistan | Philippines | Portugal | Russia | Slovakia | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Bronchiectasis|Cystic Fibrosis|Gram-Negative Bacterial Infections|Pseudomonas Infections|Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TQD3519-CS-01 | P3 |
Recruiting |
Gram-Negative Bacterial Infections |
2026-03-01 |
66% |
| ACTRN12624000601538 | P3 |
Not yet recruiting |
Cystic Fibrosis |
2025-08-29 |
|
| ERADICATE | P2 |
Active, not recruiting |
Bronchiectasis |
2024-12-18 |
|
| COPILOT | P3 |
Active, not recruiting |
Cystic Fibrosis|Pulmonary Fibrosis|Pseudomonas Infections |
2023-01-11 |